MedTrace Logo

Maraviroc in Rheumatoid Arthritis

NCT00427934 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2014-11-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Maraviroc

300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.

DRUG

Maraviroc Placebo

Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States
  • Australia
  • Germany
  • India
  • Italy
  • Mexico
  • Portugal
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427934 on ClinicalTrials.gov